v3.25.2
Condensed Consolidated Statements of Stockholders’ Equity - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Accumulated Other Comprehensive (Loss) Income
Beginning balance (in shares) at Dec. 31, 2023   68,155,830      
Beginning balance at Dec. 31, 2023 $ 247,064 $ 70 $ 532,128 $ (285,143) $ 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   277,309      
Exercise of stock options 2,307   2,307    
Exercise of warrants (in shares)   41,685      
Exercise of warrants 94   94    
Vesting of restricted stock units (in shares)   965,238      
Vesting of restricted stock units 0 $ 1 (1)    
Taxes paid related to the settlement of equity awards, net of settlement proceeds received (8,110)   (8,110)    
Stock-based compensation expense 8,261   8,261    
Change in foreign currency translation adjustment 1       1
Net income (loss) (9,777)     (9,777)  
Ending balance (in shares) at Mar. 31, 2024   69,440,062      
Ending balance at Mar. 31, 2024 239,840 $ 71 534,679 (294,920) 10
Beginning balance (in shares) at Dec. 31, 2023   68,155,830      
Beginning balance at Dec. 31, 2023 247,064 $ 70 532,128 (285,143) 9
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Change in foreign currency translation adjustment (3)        
Net income (loss) (20,741)        
Ending balance (in shares) at Jun. 30, 2024   74,132,201      
Ending balance at Jun. 30, 2024 326,716 $ 74 632,520 (305,884) 6
Beginning balance (in shares) at Mar. 31, 2024   69,440,062      
Beginning balance at Mar. 31, 2024 239,840 $ 71 534,679 (294,920) 10
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   129,968      
Exercise of stock options 1,006   1,006    
Exercise of warrants (in shares)   88,212      
Exercise of warrants 1,055   1,055    
Vesting of restricted stock units (in shares)   428,378      
Taxes paid related to the settlement of equity awards, net of settlement proceeds received (7,834)   (7,834)    
Stock-based compensation expense 11,159   11,159    
Settlement of convertible notes (in shares)   341,877      
Settlement of convertible notes 5,751   5,751    
Issuance of common stock net of underwriting discounts, commissions, and issuance costs (in shares)   3,703,704      
Issuance of common stock net of underwriting discounts, commissions, and issuance costs 86,707 $ 3 86,704    
Change in foreign currency translation adjustment (4)       (4)
Net income (loss) (10,964)     (10,964)  
Ending balance (in shares) at Jun. 30, 2024   74,132,201      
Ending balance at Jun. 30, 2024 $ 326,716 $ 74 632,520 (305,884) 6
Beginning balance (in shares) at Dec. 31, 2024 75,404,996 75,404,996      
Beginning balance at Dec. 31, 2024 $ 358,545 $ 75 648,124 (289,698) 44
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   346,874      
Exercise of stock options 3,039   3,039    
Vesting of restricted stock units (in shares)   644,538      
Vesting of restricted stock units 0 $ 1 (1)    
Taxes paid related to the settlement of equity awards, net of settlement proceeds received (856)   (856)    
Stock-based compensation expense 10,173   10,173    
Shares issued in connection with an acquisition (in shares)   22,252      
Shares issued in connection with an acquisition 1,000   1,000    
Change in foreign currency translation adjustment 1       1
Net income (loss) 4,378     4,378  
Ending balance (in shares) at Mar. 31, 2025   76,418,660      
Ending balance at Mar. 31, 2025 $ 376,280 $ 76 661,479 (285,320) 45
Beginning balance (in shares) at Dec. 31, 2024 75,404,996 75,404,996      
Beginning balance at Dec. 31, 2024 $ 358,545 $ 75 648,124 (289,698) 44
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares) 857,159        
Change in foreign currency translation adjustment $ (100)        
Net income (loss) $ 11,384        
Ending balance (in shares) at Jun. 30, 2025 77,516,232 77,516,232      
Ending balance at Jun. 30, 2025 $ 366,658 $ 78 644,950 (278,314) (56)
Beginning balance (in shares) at Mar. 31, 2025   76,418,660      
Beginning balance at Mar. 31, 2025 376,280 $ 76 661,479 (285,320) 45
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options (in shares)   510,285      
Exercise of stock options 2,763 $ 1 2,762    
Vesting of restricted stock units (in shares)   587,287      
Vesting of restricted stock units 1 $ 1 0    
Taxes paid related to the settlement of equity awards, net of settlement proceeds received (1,142)   (1,142)    
Stock-based compensation expense 15,579   15,579    
Purchase of capped calls related to the June 2025 Convertible Notes (33,728)   (33,728)    
Change in foreign currency translation adjustment (101)       (101)
Net income (loss) $ 7,006     7,006  
Ending balance (in shares) at Jun. 30, 2025 77,516,232 77,516,232      
Ending balance at Jun. 30, 2025 $ 366,658 $ 78 $ 644,950 $ (278,314) $ (56)